- Ongoing, recruitingTherapeutic exploratory (Phase II)
Rescue Therapy with the Human Anti-CD38 Antibody MOR202 (felzartamab) in Patients with Membranous Nephropathy who Failed Anti-CD20 Target Therapy (MONET study)
This study looks at a new medicine called felzartamab for people with a kidney condition called membranous nephropathy, who haven't improved with other treatments. It aims to see if the new medicine can reduce protein in their urine and help their kidneys get better.
For: Membranous nephropathyItaly - RecruitingPHASE3
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
This study looks at a new medicine called felzartamab for adults with a kidney disease called IgA nephropathy (IgAN). Researchers want to see if it reduces protein in the urine and helps kidney function. It involves infusions and careful monitoring.
For: Immunoglobulin A Nephropathy (IgAN)United States · Argentina · Australia